[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626146":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":39,"locations":48,"responsibleParty":66,"collaborators":68,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":31,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":31,"enrollmentInfo":80,"targetDuration":31,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":51,"whyStopped":31,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Quantec Ltd","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1: Study Product 50mg Dose","EXPERIMENTAL","50mg of Study Product",[13],"Dietary Supplement: Immune Defense Protein 50mg Dose",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2: Study Product 200mg Dose","200mg of Study Product",[18],"Dietary Supplement: IDP 200mg Dose",{"label":20,"type":21,"description":22,"interventionNames":23},"Group 3: Matching Placebo","PLACEBO_COMPARATOR","Participants will receive Matching Placebo",[24],"Dietary Supplement: Matching Placebo",[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DIETARY_SUPPLEMENT","Immune Defense Protein 50mg Dose","IDP dose of 50mg",[9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"IDP 200mg Dose","IDP dose of 200mg",[15],{"type":27,"name":37,"description":37,"armGroupLabels":38,"otherNames":31},"Matching Placebo",[20],[40,45],{"name":41,"role":42,"phone":43,"phoneExt":31,"email":44},"Noah Craft, M.D., Ph.D","CONTACT","213-328-0919","noah@peoplescience.health",{"name":46,"role":42,"phone":31,"phoneExt":31,"email":47},"Azure Grant","azure@peoplescience.health",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"People Science, Inc.","RECRUITING","Los Angeles","California","90045","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-118.24368,34.05223,{"lat":61,"lon":60},[64,65],{"name":41,"role":42,"phone":43,"phoneExt":31,"email":44},{"name":46,"role":42,"phone":31,"phoneExt":31,"email":47},{"type":67,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[69],{"name":50,"class":6},"100626146","immune-defense-protein-impact-on-respiratory-immune-outcomes-100626146",false,"NCT07431840","Immune Defense Protein Impact On Respiratory Immune Outcomes","A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of IDP® Supplement on Respiratory Immune Health Outcomes During Cold and Flu Season in Older Individuals","Inclusion Criteria:\n\n1. Age 60 years and older\n2. Individuals who experience upper respiratory symptoms (e.g. coughing, sneezing, congestion) at least 2-3 times during the cold\u002Fflu season.\n3. Able to read and understand English.\n4. Able to read, understand, and provide informed consent.\n5. Able to use a personal smartphone device and download Chloe by People Science.\n6. Able to receive shipment of the product at an address within the United States.\n\nExclusion Criteria:\n\nAny potential participants who:\n\n1. Do not have a personal smartphone, internet access, or unwilling to download Chloe.\n2. Already in an immunocompromised state, including:\n\n   A. Infectious Causes\n   * HIV\u002FAIDS\n   * Chronic hepatitis B or C (advanced stages)\n   * Tuberculosis (especially disseminated or extrapulmonary TB) B. Cancer-Related\n   * Leukemia (e.g., AML, ALL, CLL)\n   * Lymphoma (e.g., Hodgkin's and Non-Hodgkin's)\n   * Multiple Myeloma\n   * Any metastatic cancer receiving chemotherapy\n\n   C. Immunosuppressive Therapy:\n\n   Participants on:\n   * Corticosteroids (e.g., ≥20 mg\u002Fday of prednisone for ≥2 weeks)\n   * Biologics (e.g., TNF inhibitors like infliximab, adalimumab)\n   * Calcineurin inhibitors (e.g., tacrolimus, cyclosporine)\n   * mTOR inhibitors (e.g., sirolimus)\n   * JAK inhibitors (e.g., tofacitinib)\n   * Chemotherapy or radiation therapy\n   * Anti-rejection meds post-organ transplant D. Transplant Patients\n   * Solid organ transplant (kidney, liver, heart, lung)\n   * Hematopoietic stem cell transplant (HSCT) E. Autoimmune or Inflammatory Diseases (especially when treated with immunosuppressants)\n   * Rheumatoid Arthritis\n   * Systemic Lupus Erythematosus (SLE)\n   * Psoriasis or Psoriatic Arthritis\n   * Inflammatory Bowel Disease (Crohn's disease, Ulcerative colitis)\n   * Multiple Sclerosis (especially on disease-modifying therapies)\n3. Other Concomitant Conditions and Therapies:\n\n   1. Any investigational therapies or treatments within 30 days prior to enrollment.\n   2. Known diagnosis of Asthma and\u002For COPD\n   3. Currently diagnosed with Alcohol Use Disorder and\u002For Substance Use Disorder\n   4. Any underlying medical conditions or comorbidities that may confound the evaluation of the study outcomes\n   5. Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes\n4. Use of cannabis-containing products daily\n5. Use of nicotine-containing products daily\n6. Known hypersensitivity or previous allergic reaction to milk products, Sorbitol and\u002For tabletting aids.\n7. Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.",true,"ALL","60 Years",{"count":81,"type":82},300,"ESTIMATED","INTERVENTIONAL",[85],"NA","The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.",[88,89,90],"Upper Respiratory Disease","Influenza","Viral Upper Respiratory Infection",[92,93,90,94,89,95,96,97,98],"Cold","Flu","URI","Lungs","Upper Respiratory Tract","Upper Respiratory","Pneumonia","2026-03-10",{"date":101,"type":102},"2026-03-12","ACTUAL",{"date":104,"type":102},"2025-12-05",{"date":106,"type":82},"2026-07-31",{"name":5,"class":6},1]